FDA expands Chantix warnings to include increased heart risks
The black-box warning on Pfizer’s smoking-cessation drug Chantix (varenicline) just got bigger, following the results of a new study that found the drug caused an increased risk of heart attack and other adverse cardiac events in some patients. According to the U.S. Food and Drug Administration, the warning on Chantix labeling will include information about the safety and effectiveness of the drug in patients with existing cardiovascular disease and those with chronic obstructive pulmonary disease (COPD).